SCHEMBL6086038

SCHEMBL6086038

Cc1onc(-c2c(F)cccc2Cl)c1C(=O)Nc1ccc(-c2n[nH]cc2-c2nc3cc(Cl)ccc3o2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 2/20 0.53
LMNA P02545 1/20 0.53
HPGD P15428 1/20 0.53
HTT P42858 1/20 0.53
ATM Q13315 1/20 0.53
PTGS2 P35354 7/20 0.52
MAPT P10636 3/20 0.52
TP53 P04637 2/20 0.52
TYMS P04818 1/20 0.51
KDM4E B2RXH2 3/20 0.50
NPSR1 Q6W5P4 2/20 0.50
ALDH1A1 P00352 1/20 0.50
GPBAR1 Q8TDU6 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.47
CETP P11597 2/20 0.46
THRB P10828 2/20 0.46
PPARG P37231 1/20 0.46
NCOA2 Q15596 1/20 0.46
POLB P06746 1/20 0.46
CEPT1 Q9Y6K0 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6201586 0.85 GLA (0.53) GLALMNAHPGDHTTATM
SCHEMBL6086450 0.82 MAPT (0.59) PTGS2MAPTTP53KDM4ENPSR1
SCHEMBL6085050 0.78 MAPT (0.60) LMNAPTGS2MAPTTP53KDM4E
SCHEMBL6085510 0.77 TP53 (0.61) LMNAHPGDMAPTTP53KDM4E
SCHEMBL6084729 0.77 MAPT (0.60) PTGS2MAPTTP53KDM4ENPSR1
SCHEMBL6083652 0.77 MAPT (0.68) LMNAHPGDMAPTTP53KDM4E
SCHEMBL6084901 0.76 POLB (0.62) LMNAHPGDPTGS2MAPTTP53
SCHEMBL6087376 0.76 PTGS2 (0.51) PTGS2MAPTTP53KDM4ENPSR1
SCHEMBL6084979 0.76 MAPT (0.57) HPGDPTGS2MAPTTP53KDM4E
SCHEMBL6086246 0.76 TP53 (0.56) MAPTTP53KDM4ENPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP claimed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 GLA 4035/4885LMNA 4688/4885HPGD 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.